ovarian neoplasm
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A dominant RAD51C pathogenic splicing variant predisposes to breast and ovarian cancer in the Newfoundland population due to founder effect.
|
31782267 |
2020 |
ovarian neoplasm
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The analysis also showed a substantial difference in the profile of genes contributing to either BC or OC risk, including genes specifically associated with a high risk of OC but not BC (e.g., RAD51C, and RAD51D).
|
30733081 |
2019 |
ovarian neoplasm
|
0.500 |
Biomarker
|
disease |
BEFREE |
Paired analysis of tumour-derived versus blood-derived DNA to determine the prevalence of deleterious somatic variants in OC predisposition genes (<i>ATM</i>, <i>BRCA1/2, BRIP1</i>, <i>MSH2/6</i>, <i>PALB2</i>, <i>RAD51C/D</i> and <i>TP53</i>) and the <i>PIK3CA</i> and <i>PTEN</i> genes in individuals with OC (AGO-TR1 study, NCT02222883).
|
30979843 |
2019 |
ovarian neoplasm
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Loss-of-function variants in RAD51C are associated with familial ovarian cancer, but its role in hereditary breast cancer remains unclear.
|
30949688 |
2019 |
ovarian neoplasm
|
0.500 |
Biomarker
|
disease |
BEFREE |
Population-based BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 testing can prevent 1.86%/1.91% of BC and 3.2%/4.88% of OC in UK/US women: 657/655 OC cases and 2420/2386 BC cases prevented per million.
|
29361001 |
2018 |
ovarian neoplasm
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The results of pedigree analysis showed that the proband with a large deletion on RAD51C had a family history of both breast and ovarian cancer, and the families of probands with novel BRIP1 missense variants included a male patient with breast cancer or many patients with breast cancer within the second-degree relatives.
|
28796317 |
2017 |
ovarian neoplasm
|
0.500 |
Biomarker
|
disease |
BEFREE |
The rare finding of a clearly truncating RAD51C mutation in an early-onset BC patient with a BC-only family history supports the notion that compromised RAD51C function may result in both BC and OC.
|
27622768 |
2017 |
ovarian neoplasm
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Despite a high prevalence of deleterious missense variants, most studies of RAD51C ovarian cancer susceptibility gene only provide in silico pathogenicity predictions of missense changes.
|
28829762 |
2017 |
ovarian neoplasm
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Overall, pathogenic RAD51C mutations were identified in 0.5 % of Danish families with increased risk of hereditary breast and/or ovarian cancer.
|
26740214 |
2016 |
ovarian neoplasm
|
0.500 |
Biomarker
|
disease |
BEFREE |
RAD51C has been identified as a potential tumor suppressor and a breast and ovarian cancer susceptibility gene.
|
27753535 |
2016 |
ovarian neoplasm
|
0.500 |
Biomarker
|
disease |
BEFREE |
RAD51C is primarily an ovarian cancer susceptibility gene.
|
25470109 |
2015 |
ovarian neoplasm
|
0.500 |
Biomarker
|
disease |
BEFREE |
The RAD51 paralog RAD51C has been identified as a breast and ovarian cancer susceptibility gene.
|
25292178 |
2015 |
ovarian neoplasm
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Although the cumulative frequency of RAD51C and RAD51D truncating mutations in our patients was lower than that of the BRCA1 and BRCA2 genes, it may explain OC susceptibility in approximately 3% of high-risk OC patients.
|
26057125 |
2015 |
ovarian neoplasm
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.
|
26261251 |
2015 |
ovarian neoplasm
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Biallelic RAD51C mutations cause Fanconi anemia, and monoallelic mutations predispose women to breast and ovarian cancer.
|
24800917 |
2014 |
ovarian neoplasm
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our results support that RAD51C is a rare breast and ovarian cancer susceptibility gene and may contribute to a small fraction of families including breast and ovarian cancer cases and families with only breast cancer.
|
25086635 |
2014 |
ovarian neoplasm
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Deleterious and missense mutations of RAD51C have recently been suggested to modulate the individual susceptibility to hereditary breast and ovarian cancer and unselected ovarian cancer, but not unselected breast cancer (BrC).
|
25343521 |
2014 |
ovarian neoplasm
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
There is ongoing debate whether pathogenic RAD51C alterations increase the relative risk for BC in addition to that for OC, which was estimated to be 5.88 (95% confidence interval = 2.91 to 11.88; P = 7.65 × 10(-7)).
|
24359560 |
2013 |
ovarian neoplasm
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germline RAD51C mutations in ovarian cancer susceptibility.
|
22725699 |
2013 |
ovarian neoplasm
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In the Finnish population, we have identified two founder mutations in RAD51C that increase the risk of ovarian cancer but not breast cancer in the absence of ovarian cancer.
|
23176254 |
2012 |
ovarian neoplasm
|
0.500 |
Biomarker
|
disease |
BEFREE |
An increased cancer risk has been firmly established for carriers of mutations in FANCD1/BRCA2, FANCJ/BRIP1, FANCN/PALB2, RAD51C/FANCO and link the FA pathway to inherited breast and ovarian cancer.
|
22829014 |
2012 |
ovarian neoplasm
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in RAD51C contribute marginally to breast and ovarian cancer susceptibility in ethnically diverse, Jewish high risk families.
|
23117857 |
2012 |
ovarian neoplasm
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Deleterious mutations in the RAD51C gene, which encodes a DNA double-strand break repair protein, have been reported to confer high-penetrance susceptibility to both breast and ovarian cancer.
|
22476429 |
2012 |
ovarian neoplasm
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our data confirm a consistent but low frequency (2/335 families) of inactivating RAD51C mutations among families with a history of both breast and ovarian cancer and an absence of mutations among breast cancer only families (0/1,053 families).
|
21990120 |
2012 |
ovarian neoplasm
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We have screened RAD51C sequence variants by HRMA in 492 breast cancer patients with family history of breast and/or ovarian cancer that were previously tested negative for BRCA1/2.
|
21537932 |
2011 |